Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

6-Aminocaproic acid

Related Products

Hot Products

Name

6-Aminocaproic acid

EINECS 200-469-3
CAS No. 60-32-2 Density 1.042 g/cm3
PSA 63.32000 LogP 1.29040
Solubility soluble in water Melting Point 207-209 °C (dec.)(lit.)
Formula C6H13NO2 Boiling Point 255.6 °C at 760 mmHg
Molecular Weight 131.175 Flash Point 108.4 °C
Transport Information N/A Appearance white crystalline powder
Safety 26-36 Risk Codes 36/37/38
Molecular Structure Molecular Structure of 60-32-2 (6-Aminocaproic acid) Hazard Symbols IrritantXi
Synonyms

Caproicacid, e-amino- (3CI);6-Amino-n-hexanoic acid;6-Aminocaproic acid;6-Aminohexanoic acid;ACS;Acepramin;Amicar;Amikar;CL10304;CY 116;Caplamin;Capramol;Caprolisin;EACA;Epsamon;Epsicapron;Epsilon S;Hemocaprol;Hemopar;Hepin;NSC 212532;NSC 26154;NSC 400230;e-Amino-n-hexanoic acid;e-Aminocaproic acid;e-Leucine;e-Norleucine;w-Aminocaproic acid;w-Aminohexanoic acid;

Article Data 115

6-Aminocaproic acid Consensus Reports

Reported in EPA TSCA Inventory.

6-Aminocaproic acid Specification

The 6-Aminocaproic acid is an organic compound with the formula C6H13NO2. The IUPAC name of this chemical is 6-aminohexanoic acid. With the CAS registry number 60-32-2, it is also named as Acide aminocaproique. The product's categories are Amino Acids; Organic Acids; omega-Aminocarboxylic Acids; omega-Functional Alkanols, Carboxylic Acids, Amines & Halides; Fibrinogen/Thrombin. Besides, it is a white crystalline powder, which should be stored in a closed and dark place.

Physical properties about 6-Aminocaproic acid are: (1)ACD/LogP: -0.11; (2)ACD/LogD (pH 5.5): -2.65; (3)ACD/LogD (pH 7.4): -2.61; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1; (8)#H bond acceptors: 3; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 6; (11)Polar Surface Area: 29.54 Å2; (12)Index of Refraction: 1.467; (13)Molar Refractivity: 34.94 cm3; (14)Molar Volume: 125.8 cm3; (15)Polarizability: 13.85×10-24cm3; (16)Surface Tension: 42.6 dyne/cm; (17)Density: 1.042 g/cm3; (18)Flash Point: 108.4 °C; (19)Enthalpy of Vaporization: 54.29 kJ/mol; (20)Boiling Point: 255.6 °C at 760 mmHg; (21)Vapour Pressure: 0.00495 mmHg at 25°C.

Preparation: this chemical is derived from the hydrolysis of caprolactam.

Uses of 6-Aminocaproic acid: it is used to treat excessive postoperative bleeding, especially after procedures in which a great amount of bleeding is indicated, such as cardiac surgery. It can be given orally or intravenously. A meta-analysis found that lysine analogs like aminocaproic acid significantly reduced blood loss in patients undergoing coronary artery bypass grafting. 6-Aminocaproic acid can also be used to treat the overdose and/or toxic effects of the thrombolytic pharmacologic agents tissue plasminogen activator (commonly known as tPA) and streptokinase.

When you are using this chemical, please be cautious about it as the following:
This chemical is irritating to eyes, respiratory system and skin. When you are using it, wear suitable protective clothing. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)CCCCCN
(2)InChI: InChI=1/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
(3)InChIKey: SLXKOJJOQWFEFD-UHFFFAOYAY
(4)Std. InChI: InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
(5)Std. InChIKey: SLXKOJJOQWFEFD-UHFFFAOYSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral > 7gm/kg (7000mg/kg)   Drugs in Japan Vol. 6, Pg. 79, 1982.
dog LDLo intravenous 2150mg/kg (2150mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Pharmacologist. Vol. 3, Pg. 62, 1961.
guinea pig LDLo intravenous 19800mg/kg (19800mg/kg)   Anesthesie, Analgesie, Reanimation. Vol. 22, Pg. 481, 1965.
man TDLo multiple routes 14400mg/kg/59 (14400mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

KIDNEY, URETER, AND BLADDER: HEMATURIA
British Journal of Urology. Vol. 60, Pg. 81, 1987.
man TDLo oral 1778mg/kg/8D- (1778mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"

KIDNEY, URETER, AND BLADDER: HEMATURIA
American Journal of Kidney Diseases. Vol. 8, Pg. 441, 1986.
monkey LD50 intravenous > 2gm/kg (2000mg/kg)   Drugs in Japan Vol. 6, Pg. 79, 1982.
monkey LD50 oral > 7gm/kg (7000mg/kg)   Drugs in Japan Vol. 6, Pg. 79, 1982.
mouse LD50 intravenous 4900mg/kg (4900mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Anesthesie, Analgesie, Reanimation. Vol. 22, Pg. 481, 1965.
mouse LD50 oral 14300mg/kg (14300mg/kg)   Drugs in Japan Vol. 6, Pg. 79, 1982.
mouse LD50 subcutaneous 5790mg/kg (5790mg/kg)   Drugs in Japan Vol. -, Pg. 62, 1995.
rabbit LD50 intravenous 2gm/kg (2000mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 9, Pg. 759, 1967.
rat LD oral > 10gm/kg (10000mg/kg)   Pharmacologist. Vol. 3, Pg. 62, 1961.
rat LD50 intraperitoneal 7gm/kg (7000mg/kg)   Pharmacologist. Vol. 3, Pg. 62, 1961.
rat LD50 intravenous 3300mg/kg (3300mg/kg)   Pharmacologist. Vol. 3, Pg. 62, 1961.
women TDLo oral 12600mg/kg/5W (12600mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"
Postgraduate Medical Journal. Vol. 55, Pg. 282, 1979.
women TDLo oral 33600mg/kg/14 (33600mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION
Postgraduate Medical Journal. Vol. 55, Pg. 282, 1979.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 60-32-2